ATOS ATOS
Company Profile ↓Company Overview
ATOS (ATOS) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -95.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 4.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.05% |
| 1 Year: | -95.62% |
Stock Price Performance
| 1 Year: | -80.80% |
| 6 Months: | -56.78% |
| 3 Months: | -57.17% |
| 1 Month: | -4.02% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 86.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 182.67K | 326.08K | 76.60K | 24.12K | 9.88K | 3.43K | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 116.21K | 103.92K | 50.66K | 24.12K | 9.88K | 3.43K | 0 | 0 | 458.84K | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -1.94M | -2.58M | -3.50M | -2.41M | -3.19M | -3.25M | -3.27M | -3.17M | -3.84M | -2.33M | -1.72M | -1.56M | -1.70M | -1.90M | -2.06M | -1.87M | -4.14M | -3.31M | -4.06M | -7.29M | -3.30M | -2.94M | -3.94M | -3.51M | -3.53M | -7.00M | -5.16M | -4.75M | -6.59M | -8.21M | -7.10M | -7.79M | -7.47M | -6.98M | -7.11M | -6.38M | -7.41M | -9.04M | -9.25M | -9.87M |
| Net Income | -1.94M | -2.58M | -3.50M | -2.41M | -3.19M | -3.25M | -3.34M | -3.15M | -4.32M | -2.33M | -1.72M | 204.69K | -1.70M | -2.24M | -2.18M | -1.87M | -4.14M | -3.31M | -4.07M | -7.26M | -3.29M | -2.95M | -3.91M | -3.49M | -3.54M | -7.04M | -5.20M | -4.79M | -6.67M | -8.01M | -6.28M | -9.83M | -6.23M | -5.88M | -6.05M | -7.23M | -6.72M | -8.42M | -8.69M | -9.59M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.05 | -0.08 | -0.05 | -0.05 | -0.05 | -0.06 | -0.78 | -0.07 | -0.07 | -1.11 |
| R&D Expense | 220.19K | 189.96K | 321.11K | 422.50K | 510.77K | 923.17K | 565.80K | 373.47K | 948.96K | 149.97K | 168.99K | 85.00K | 544.30K | 824.09K | 742.45K | 470.98K | 1.47M | 1.42M | 1.45M | 2.61M | 1.68M | 938.62K | 1.65M | 1.66M | 1.38M | 3.80M | 2.21M | 1.50M | 3.43M | 5.16M | 3.51M | 3.71M | 4.47M | 3.75M | 3.55M | 3.41M | 4.16M | 5.50M | 5.37M | 4.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.50K | 481.84K | 632.56K | 40.14K | 1.76K | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | -95.69K | 416.21K | 137.09K | 40.14K | -130.65K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -3.43M | -5.07M | -10.78M | -12.17M | -12.76M | -7.97M | -7.65M | -11.43M | -17.27M | -14.61M | -20.52M | -27.69M | -31.38M | -27.62M | -37.14M |
| Net Income | -1.09M | -3.44M | -5.08M | -10.78M | -14.66M | -15.76M | -6.37M | -8.12M | -11.40M | -17.24M | -17.83M | -20.61M | -26.96M | -30.09M | -25.50M | -34.77M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.21 | -0.24 | -3.04 | -4.04 |
| R&D Expense | - | - | 1.97M | 1.11M | 1.11M | 2.36M | 770.43K | 2.33M | 4.21M | 6.65M | 6.61M | 9.21M | 15.08M | 17.33M | 14.12M | 21.18M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2009 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 3.07M | 6.83M | 12.01M | 11.76M | 6.24M | 4.14M | 8.16M | 11.72M | 14.49M | 42.84M | 141.26M | 123.53M | 96.25M | 76.44M | 47.61M |
| Total Equity | 54.00K | 31.68K | -851.85K | 1.56M | 5.18M | 10.60M | 9.50M | 3.74M | 3.10M | 6.94M | 8.81M | 13.16M | 27.17M | 138.14M | 117.96M | 91.02M | 71.48M | 39.35M |
| Cash & Equivalents | 0 | - | 10.25K | 1.91M | 1.73M | 6.34M | 8.50M | 3.72M | 3.03M | 7.22M | 10.38M | 12.58M | 39.55M | 136.38M | 110.89M | 88.46M | 71.08M | 41.30M |
| Total Liabilities | - | - | - | - | - | 1.41M | 2.27M | 2.50M | 1.05M | - | 2.92M | 1.33M | 15.67M | 3.13M | 5.57M | 5.24M | 4.97M | 8.26M |
| Current Liabilities | - | - | - | 1.51M | 1.65M | 1.40M | 2.26M | 2.50M | 1.05M | 1.23M | 2.92M | 1.32M | 15.67M | 3.13M | 5.57M | 5.24M | 4.97M | 8.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.49M | -3.90M | -10.56M | -13.95M | -5.37M | -6.59M | -8.96M | -9.13M | -11.57M | -16.47M | -20.76M | -20.94M | -21.03M | -29.76M |
| Investing Cash Flow | -136.93K | -134.58K | -343.26K | -288.42K | -9.21K | - | -110.91K | -7.62K | -9.00K | -9.00K | -4.73M | -14.00K | -19.00K | -23.00K |
| Financing Cash Flow | 5.53M | 3.85M | - | - | 4.70M | 10.78M | 12.29M | 11.34M | 38.55M | 113.30M | 0 | -1.48M | 3.67M | 0 |
| Capital Expenditure | - | - | - | - | - | - | -110.91K | -7.62K | -9.00K | -9.00K | -27.00K | -14.00K | -19.00K | -23.00K |
| Free Cash Flow | - | - | - | - | - | - | -9.07M | -9.14M | -11.58M | -16.48M | -20.79M | -20.95M | -21.05M | -29.79M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | 0 | 1.48M | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | -6,379.3% | 86.4% | 21.7% | 100.0% | -7,431.9% | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | -228,612.7% | -1,052.0% | -1,704.9% | -30,323.0% | -725,746.2% | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | -229,484.5% | -1,054.3% | -1,704.9% | -36,518.8% | -896,491.6% | - | - | - | - | - | - | - | - | - | - |
| ROE % | 127.6% | -220.7% | -98.2% | -101.7% | -154.3% | -421.2% | -205.6% | -117.1% | -129.5% | -131.0% | -65.6% | -14.9% | -22.9% | -33.1% | -35.7% | -88.4% |
| ROCE % | - | -219.9% | -97.9% | -101.7% | -128.1% | -341.0% | -257.3% | -110.2% | -129.9% | -131.1% | -53.8% | -14.9% | -23.5% | -34.5% | -38.6% | -94.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATOS
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNRjNZMk51a1lKYjRHV1AycHdqR1I1SzdpeHpPckJxZWhSR1JvLXd6dWh6bjkwVHVRdUpCUE9qVzNwLXlaTFpVXy1UUHFMdTNiTkRXTlFLYkx3U1ZnTEdZejQyejNVY0hBb2Z1MThQX29XcUR6R25IajJNeFpXT0M5QUo3RnU3MlBsSFBGOU…
Atos (ENXTPA:ATO) Stock Faces Debt Strain Despite Narrower First Half Loss - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9ZTXpVSWhWcTZjcDF0OXNQMGVtU3pSdTc4aEFXZmtSNEFfOUxLZTJra2NVZXFkbDN5TkJid2twQ0d1XzJScHN0c1ZCUEtqOXoyQTlvLVA2ZVg?oc=5" target="_blank">Atos (ENXTPA:ATO) Stock Faces Debt Strain Despit…
Atos share rebounds 2.5% and moves back above its 20-day moving average - Idéal Investisseur
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNSE1oQlRCNjQxQ0ZQUlJzRzR2VHRQTUdrTUhMMGY3dFJOZk10a25lUjl5OXJkbzZYR0gtVUQtazJ3UlhsZF9aNkdqUHplSk5JckVuemZlN1hITTNVbjZVSWFtWlM3emZyT3VrNTF2Z0J6bm11c2UtcEZ6YmhvOFo2eXQ4V2dZSG4welBYVn…
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi8AFBVV95cUxPeTBScUZETEZ3OWhJWnFScUZUalRXVzZIZnNIV2xaVm5ZUDJQMkx3QVdCdFdXUVhGOEdBWE9zZmo0SHdySXNLVFhYSmVZTm5pRmpoTmx1cXdWaWxFUXpmMEVMaUNoMVFKMUJvTFg2aEN6ZVhVeE5Sb0RJY0hWalNQVTJxczFvMi1KYWxvbW…
Five New Compounds Show Activity in Breast Cancer Models With ESR1 Mutations - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNeHNZNUF6SjFDbkl4UWZ0SVFEUVQzTVNzNHowNkRoSjdxRnloVjBpRGFOQUllT0FkaEtubXVVYkhaa3hjSlM5alo3SXRxZ0JwRzRtMDd5alc0c2kyTVpXblZIQmZoSGJoZzNSdkFNYngxU1E0X3VjOGp0TkdyUlRZZ2l6Szk3cU1MYXp0dk…
Is Atos (ENXTPA:ATO) Pricing In A Sustainable Recovery After Recent Share Surge? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxPekZ5U1BUMjRmaVpHMDhsNExINHdpaW5sZFZpSlhVYU9DTEg0bVZ0OFk3R1lSalhoaW9JSzk2ekNrOG1sR2I0Z0dRZk9TU2l4cUV0NlBld1VwNWlvLVZOVUpRMlp2cHFYTnNDdlkwUEROZlowUkV4bkQwNm9zcnVHY2I3MHU4a1h3?oc=5"…
ATOS — Frequently Asked Questions
What is the current share price of ATOS?
As of 2026-08-05 17:25 PDT, ATOS trades at $2.39 on NASDAQ/NYSE. Its 52-week range is $1.75 to $17.70.
What is the P/E ratio of ATOS?
ATOS trades at a trailing price-to-earnings (P/E) ratio of -0.59.
What is the return on equity (ROE) of ATOS?
ATOS has a return on equity (ROE) of -88.35%. Its return on capital employed (ROCE) is -94.38%.
Is ATOS a good stock to buy?
This page provides a data-driven analysis of ATOS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.